Lexicon Pharmaceuticals vs Alphabet Which Is More Lucrative?

Lexicon Pharmaceuticals and Alphabet (the parent company of Google) are two well-known stocks in the technology and healthcare sectors. Lexicon is a biopharmaceutical company focused on developing innovative treatments for various diseases, while Alphabet is a technology conglomerate known for its dominance in search engines, online advertising, and other tech-related services. Both companies have shown strong financial performance and growth potential, making them attractive options for investors looking to diversify their portfolios.

Lexicon Pharmaceuticals

Alphabet

Stock Price
Day Low$0.78
Day High$0.98
Year Low$0.62
Year High$3.73
Yearly Change501.61%
Revenue
Revenue Per Share$0.01
5 Year Revenue Growth-0.99%
10 Year Revenue Growth-0.82%
Profit
Gross Profit Margin0.88%
Operating Profit Margin-40.37%
Net Profit Margin-41.09%
Stock Price
Day Low$193.29
Day High$196.71
Year Low$131.06
Year High$196.89
Yearly Change50.23%
Revenue
Revenue Per Share$27.64
5 Year Revenue Growth1.47%
10 Year Revenue Growth4.42%
Profit
Gross Profit Margin0.58%
Operating Profit Margin0.31%
Net Profit Margin0.28%

Lexicon Pharmaceuticals

Alphabet

Financial Ratios
P/E ratio-1.38
PEG ratio-0.01
P/B ratio1.66
ROE-107.38%
Payout ratio0.00%
Current ratio7.45
Quick ratio7.43
Cash ratio0.96
Dividend
Dividend Yield-%
5 Year Dividend Yield0.00%
10 Year Dividend Yield0.00%
Lexicon Pharmaceuticals Dividend History
Financial Ratios
P/E ratio25.03
PEG ratio3.75
P/B ratio7.51
ROE31.66%
Payout ratio5.22%
Current ratio1.95
Quick ratio1.95
Cash ratio0.25
Dividend
Dividend Yield0.31%
5 Year Dividend Yield0.00%
10 Year Dividend Yield0.00%
Alphabet Dividend History

Lexicon Pharmaceuticals or Alphabet?

When comparing Lexicon Pharmaceuticals and Alphabet, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Lexicon Pharmaceuticals and Alphabet.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Lexicon Pharmaceuticals has a dividend yield of -%, while Alphabet has a dividend yield of 0.31%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Lexicon Pharmaceuticals reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Alphabet reports a 5-year dividend growth of 0.00% year and a payout ratio of 5.22%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Lexicon Pharmaceuticals P/E ratio at -1.38 and Alphabet's P/E ratio at 25.03. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Lexicon Pharmaceuticals P/B ratio is 1.66 while Alphabet's P/B ratio is 7.51.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Lexicon Pharmaceuticals has seen a 5-year revenue growth of -0.99%, while Alphabet's is 1.47%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Lexicon Pharmaceuticals's ROE at -107.38% and Alphabet's ROE at 31.66%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $0.78 for Lexicon Pharmaceuticals and $193.29 for Alphabet. Over the past year, Lexicon Pharmaceuticals's prices ranged from $0.62 to $3.73, with a yearly change of 501.61%. Alphabet's prices fluctuated between $131.06 and $196.89, with a yearly change of 50.23%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.

Comparision